Profile: Proximagen Neuroscience Plc (PRXN.L)

PRXN.L on London Stock Exchange

110.00GBp
11:30am EST
Price Change (% chg)

0.00p (+0.00%)
Prev Close
110.00p
Open
110.00p
Day's High
110.00p
Day's Low
110.00p
Volume
0
Avg. Vol
152
52-wk High
157.00p
52-wk Low
102.00p

view overview for:

Full Description

Proximagen Neuroscience plc is engaged in discovery and development of therapeutic treatments for neurodegenerative disease. The Company is focused on developing drugs for the treatment of age-related neurodegenerative disorders, including Parkinson’s disease and Alzheimer’s disease. The Company’s wholly owned subsidiary is Proximagen Limited, which is engaged in neuroscience research. In November 2009, the Company completed the acquisition of Cambridge Biotechnology Ltd.
» Full Overview of PRXN.L

Company Address

Proximagen Neuroscience Plc

Hodgkin Building, Guy's Campus
King's College London
London     SE1 1UL
P: +44207.8486938
F: +44207.8486034

Company Web Links

Officers & Directors

Name Compensation
Allen, Peter --
Mulvany, Kenneth 287,410
Hunter, James 209,240
Jenner, Peter --
Paddock, June --
» More Officers & Directors

Proximagen Neuroscience Plc News

view overview for: